Key Takeaways for PrEP, HIV Treatment and Other Infectious Diseases
|
One of the highlights regarding HIV prevention was
a study looking at lenacapavir (LEN; Gilead) once yearly for pre-exposure
prophylaxis (PrEP). (LEN ... |
FDA slaps clinical hold on multiple Gilead HIV trials
Gilead has been hit with a clinical hold from the FDA for five tests of its experimental HIV combination treatment amid safety concerns. View article...